Loading...
•
Jun 30, 2025
•/
GSK Q2 2025 Earnings Report
GSK reported strong Q2 performance with solid revenue growth and EPS expansion driven by Specialty Medicines.
Key Takeaways
GSK posted a robust quarter with £7.99 billion in revenue and £1.89 billion in net income. EPS rose to 46.5p as operating profit margins improved, supported by growth in Specialty Medicines and pipeline progress.
Revenue reached £7.99 billion, up from £7.88 billion last year
EPS rose to 46.5p from 43.4p, driven by improved margins
Net income totaled £1.89 billion in the quarter
Cash generated from operations grew to £3.73 billion
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
GSK expects to deliver toward the top end of FY2025 guidance, driven by strong Specialty Medicines performance, robust pipeline momentum, and improved operational efficiency.
Positive Outlook
- FY2025 sales guidance reaffirmed at 3–5% growth
- Core EPS expected to grow 6–8%
- Specialty Medicines growth upgraded to low teens %
- HIV portfolio forecast raised to mid-to-high single digit %
- Strong cash flow supports investment and shareholder returns
Challenges Ahead
- Vaccines guidance revised to low single digit decline to stable
- General Medicines expected to remain broadly stable
- R&D costs expected to grow ahead of sales
- Currency headwinds projected to impact Sterling results by ~4%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...